PLx Pharma Inc. (PLXP) Analysts See $-0.51 EPS

January 22, 2018 - By Marguerite Chambers

 PLx Pharma Inc. (PLXP) Analysts See $ 0.51 EPS

Analysts expect PLx Pharma Inc. (NASDAQ:PLXP) to report $-0.51 EPS on February, 8.After having $-0.44 EPS previously, PLx Pharma Inc.’s analysts see 15.91 % EPS growth. The stock increased 4.55% or $0.3 during the last trading session, reaching $6.9. About 41,466 shares traded or 245.67% up from the average. PLx Pharma Inc. (NASDAQ:PLXP) has 0.00% since January 22, 2017 and is . It has underperformed by 16.70% the S&P500.

PLx Pharma Inc., a late-stage specialty pharmaceutical company, focuses on developing nonsteroidal anti-inflammatory drugs and other pharmaceutical agents. The company has market cap of $60.18 million. The Company’s lead product is Aspertec 325 mg, a novel formulation of aspirin that uses the PLxGuard delivery system to reduce acute gastrointestinal side effects while providing antiplatelet effectiveness for cardiovascular disease prevention. It currently has negative earnings. The company??s product pipeline also includes other oral nonsteroidal anti-inflammatory drugs using the PLxGuard delivery system, including PL1200 Ibuprofen 200 mg, a clinical-stage GI-safer ibuprofen product for pain and inflammation; and Aspertec 81 mg, a novel formulation of aspirin, which is in late-stage development.

More notable recent PLx Pharma Inc. (NASDAQ:PLXP) news were published by: which released: “Dipexium shares surge on announced merger with PLx Pharma” on December 22, 2016, also with their article: “Dipexium and PLx Pharma Announce Merger Agreement” published on December 22, 2016, published: “PLx Pharma and Dipexium Pharmaceuticals Complete Merger” on April 19, 2017. More interesting news about PLx Pharma Inc. (NASDAQ:PLXP) were released by: and their article: “PLx Pharma Inc. Reports Second Quarter 2017 Results” published on August 10, 2017 as well as‘s news article titled: “PLx Pharma Inc. Reports Third Quarter 2017 Results” with publication date: November 09, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: